Browsing Molecular Pathology by author "Kaiser, Martin"
Now showing items 1-20 of 61
-
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.
Cook, G; Royle, K-L; Pawlyn, C; Hockaday, A; Shah, V; et al. (ELSEVIER SCI LTD, 2019-03-01)BACKGROUND: Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict ... -
A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
Bødker, JS; Brøndum, RF; Schmitz, A; Schönherz, AA; Jespersen, DS; et al. (ELSEVIER, 2018-09-25)Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and ... -
Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
Campbell, JP; Heaney, JLJ; Pandya, S; Afzal, Z; Kaiser, M; et al. (NATURE PUBLISHING GROUP, 2017-09-05)BACKGROUND: Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; ... -
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Kaiser, M; Beksaç, M; Gulbrandsen, N; Schjesvold, F; Hájek, R; et al. (SPRINGER, 2020-08-01)The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in ... -
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics.
Hoang, PH; Cornish, AJ; Sherborne, AL; Chubb, D; Kimber, S; et al. (SPRINGERNATURE, 2020-10-14)Most patients with multiple myeloma (MM) die from progressive disease after relapse. To advance our understanding of MM evolution mechanisms, we performed whole-genome sequencing of 80 IGH-translocated tumour-normal newly ... -
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.
Went, M; Sud, A; Law, PJ; Johnson, DC; Weinhold, N; et al. (NATURE PUBLISHING GROUP, 2017-06-16) -
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Pawlyn, C; Cairns, D; Menzies, T; Jones, J; Jenner, M; et al. (FERRATA STORTI FOUNDATION, 2022-01-01)Autologous stem cell transplant (ASCT) remains standard of care for consolidation after induction therapy for eligible newly diagnosed myeloma patients. In recent clinical trials comparing ASCT to delayed ASCT, patients ... -
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson, GH; Pawlyn, C; Cairns, DA; de Tute, RM; Hockaday, A; et al. (PUBLIC LIBRARY SCIENCE, 2021-01-01)BACKGROUND: Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, ... -
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials.
Heaney, JLJ; Campbell, JP; Iqbal, G; Cairns, D; Richter, A; et al. (NATURE PUBLISHING GROUP, 2018-08-01)We measured immunosuppression at myeloma diagnosis and assessed the impact on survival in 5826 UK myeloma trial patients. Polyclonal immunoglobulin levels were below normal in 85% of patients and above normal in only 0.4% ... -
Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management.
Latifoltojar, A; Boyd, K; Riddell, A; Kaiser, M; Messiou, C (ELSEVIER SCIENCE INC, 2021-01-01)Diagnosis of patients suspected of multiple myeloma requires a combination of serological and biochemical tests, bone marrow aspirate (BMA) and/or bone marrow trephine (BMT) biopsies as well as complementary information ... -
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
Weinhold, N; Salwender, HJ; Cairns, DA; Raab, MS; Waldron, G; et al. (FERRATA STORTI FOUNDATION, 2021-10-01)Not available. -
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Jones, JR; Weinhold, N; Ashby, C; Walker, BA; Wardell, C; et al. (FERRATA STORTI FOUNDATION, 2019-06-30)The emergence of treatment resistant sub-clones is a key feature of relapse in multiple myeloma. Therapeutic attempts to extend remission and prevent relapse include maximizing response and the use of maintenance therapy. ... -
Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
Sriskandarajah, P; De Haven Brandon, A; MacLeod, K; Carragher, NO; Kirkin, V; et al. (BMC, 2020-03-30)BACKGROUND: Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase ... -
Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.
Shah, V; Boyd, KD; Houlston, RS; Kaiser, MF (BMC, 2017-11-06)BACKGROUND: Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival. Long term survivorship from myeloma is very rare and despite advances in its treatment the disease is generally ... -
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
Croft, J; Ellis, S; Sherborne, AL; Sharp, K; Price, A; et al. (SPRINGERNATURE, 2020-12-01)Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multiple myeloma (MM), however their evolution in context of modern biological therapy is not well characterized. To investigate ... -
Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma.
Ahmed, N; Sriskandarajah, P; Burd, C; Riddell, A; Boyd, K; et al. (BRITISH INST RADIOLOGY, 2019-01-01)OBJECTIVE: Current therapies for multiple myeloma, which include corticosteroids, increase risk of avascular necrosis. The aim of this study was to assess incidental detection of femoral head avascular necrosis on routine ... -
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave, C; Pawlyn, C; Davies, F; Craig, Z; Cairns, D; et al. (WILEY, 2020-06-10)Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. ... -
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
Luo, MM; Usmani, SZ; Mateos, M-V; Nahi, H; Chari, A; et al. (WILEY, 2020-11-03)We report the population pharmacokinetic (PK) and exposure-response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) ... -
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.
Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; et al. (NATURE PUBLISHING GROUP, 2018-12-21)The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ... -
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.
Li, N; Johnson, DC; Weinhold, N; Kimber, S; Dobbins, SE; et al. (CELL PRESS, 2017-09-12)Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by ...